Home > Insider Trading > Filing (0000905718-21-000712)

Filing Details

Accession Number:: 0000905718-21-000712
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-05-18 18:00:19
Reporting Period:: 2021-05-13

Accepted Time:: 2021-05-18 18:00:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1831828	Vera Therapeutics Inc.	VERA	()	X0

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1397144	Llp Abingworth	38 Jermyn Street London X0 SW1Y 6DN		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2021-05-18	2,187,504	$0.00	2,187,504	No	4	C	Indirect	See Footnote
Class A Common Stock	Acquisiton	2021-05-18	772,727	$11.00	2,960,231	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Stock Option (right to buy)	Acquisiton	2021-05-13	9,925	$0.00	9,925	$11.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
9,925		2031-05-12	No	4	A	Indirect

Footnotes

The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date.
The shares are held by Abingworth Bioventures 8 LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. Abingworth LLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
The options (the "Options") will vest on the earlier of May 13, 2022 or the 2022 annual meeting of stockholders. The Options were granted to Kurt Von Emster ("Von Emster"), a member of Abingworth LLP. Abingworth LLP provides advisory services to ABV 8. Under an agreement between Von Emster and Abingworth LLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV 8, and must exercise the Option solely upon the direction of Abingworth LLP.
ABV 8 may be deemed the indirect beneficial owner of the Option, and Von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV 8. Abingworth LLP disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV 8, Von Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.